EyePoint Q1 net loss $84.8M ($0.99/share); DURAVYU Phase 3 wet AMD data expected mid-2026

EyePoint, Inc.

2026-Q1 EPS reported -$0.99 vs consensus -$0.81 ▼ miss (-21.7%)

Q1 2026 revenue $0.7M vs $24.5M YoY, driven by YUTIQ license deferral; operating expenses $87.9M.
Cash & investments $223M at March 31, 2026, runway into Q4 2027; down from $306M at year-end 2025.
Phase 3 wet AMD trials (LUGANO/LUCIA) topline data due mid-2026; over 900 patients enrolled.
Phase 3 DME trials (COMO/CAPRI) >1/3 enrolled; full enrollment expected Q3 2026, topline Q4 2027.
New ARVO 2026 data show vorolanib inhibits JAK1/IL-6, supporting multi-mechanism anti-inflammatory effect.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EyePoint, Inc. reported first quarter ended March 31, 2026 results: revenue $0.7 million, net income net loss was $84.8 million, EPS ($0.99) per share.

Period: first quarter ended March 31, 2026
Revenue: $0.7 million
Net income: net loss was $84.8 million
EPS: ($0.99) per share
Result: reported results

Exact text from the filing

or DURAVYU-related ocular or systemic SAEs. Review of Results for the First Quarter Ended March 31, 2026 For the first quarter ended March 31, 2026, total net revenue was $0.7 million compared to $24.5 million for the corresponding period in 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the Company’s 2023

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-207537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.